Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Introduction
TRAIL (TNF-Related Apoptosis-Inducing Ligand), encoded by the TNFSF10 gene, is a member of the tumor necrosis factor (TNF) superfamily that plays complex roles in cell death, immune surveillance, and neuroinflammation. Originally identified for its ability to induce apoptosis in transformed and cancer cells while sparing normal cells, TRAIL has emerged as a critical regulator of neuronal survival and death in the context of neurodegenerative diseases. In the central nervous system, TRAIL is expressed by [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), [microglia](/cell-types/microglia-neuroinflammation), and [oligodendrocytes](/cell-types/oligodendrocytes), where it participates in both physiological processes like synaptic pruning and pathological mechanisms driving neurodegeneration.
The unique feature of TRAIL signaling lies in its receptor system: TRAIL binds to four membrane-bound receptors with distinct signaling properties. Two death receptors (DR4/TRAIL-R1 and DR5/TRAIL-R2) propagate pro-apoptotic signals through caspase-8 activation, while two decoy receptors (DcR1/TRAIL-R3 and DcR2/TRAIL-R4) sequester TRAIL and prevent cell death. This elegant system allows precise control over cell fate decisions in the healthy brain, but dysregulation of TRAIL signaling contributes to the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [multiple sclerosis](/diseases/multiple-sclerosis), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis).
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRAIL — TNF-Related Apoptosis-Inducing Ligand</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TRAIL (TNFSF10)</td></tr>
<tr><td><strong>Full Name</strong></td><td>TNF Superfamily Member 10 (TNF-Related Apoptosis-Inducing Ligand)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>3q26.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[8743](https://www.ncbi.nlm.nih.gov/gene/8743)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000117586</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P50591](https://www.uniprot.org/uniprot/P50591)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>TNF superfamily, Type II transmembrane proteins</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>Apo-2L, TL2A, CD253</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis</td></tr>
</table>
</div>
Gene Structure and Protein Architecture
Gene Organization
The TNFSF10 gene spans approximately 17 kilobases on the reverse strand of chromosome 3 (3q26.1). The gene consists of six exons encoding a type II transmembrane protein of 281 amino acids. Unlike typical TNF family members, TRAIL is expressed as a membrane-bound protein that can be proteolytically cleaved to form a soluble ligand, allowing both cell-associated and secreted signaling.
Protein Structure
TRAIL is synthesized as a Type II transmembrane protein with the following structural features:
N-terminal Cytoplasmic Domain: The short N-terminus (approximately 16 amino acids) faces the cytoplasm and contains no obvious signaling motifs.
Transmembrane Helix: A hydrophobic transmembrane domain (approximately 21 amino acids) anchors the protein in the cell membrane.
C-terminal Extracellular Domain: The bulk of the protein (approximately 224 amino acids) extends extracellularly and contains:
- A stalk region connecting to the transmembrane domain
- A receptor-binding domain organized as a beta-sheet jelly-roll fold
- A C-terminal region involved in trimerization
Trimeric Structure: Like other TNF family members, TRAIL functions as a trimer. The trimeric structure is essential for high-affinity receptor binding and signaling.
Splice Variants
Several TRAIL splice variants have been identified:
- TRAIL-α — Full-length membrane-bound form
- TRAIL-β — Soluble form generated by proteolytic cleavage
- TRAIL-γ — Truncated variant with altered signaling
Receptor System and Signaling Pathways
TRAIL Receptors
TRAIL signals through a complex receptor system with four membrane-bound receptors:
| Receptor | Type | Signaling | Expression Pattern |
|----------|------|-----------|-------------------|
| DR4 (TRAIL-R1) | Death receptor | Pro-apoptotic | Wide, including neurons |
| DR5 (TRAIL-R2) | Death receptor | Pro-apoptotic | High in brain |
| DcR1 (TRAIL-R3) | Decoy receptor | Anti-apoptotic | Limited in brain |
| DcR2 (TRAIL-R4) | Decoy receptor | Anti-apoptotic | Some neurons |
Additionally, osteoprogerin (OPG) can bind TRAIL with low affinity, serving as a soluble decoy receptor.
Signaling Mechanisms
Death Receptor Signaling (DR4/DR5):
TRAIL binding → Receptor trimerization → Death domain formation
↓
FADD recruitment → Caspase-8 activation
↓
Direct pathway: Caspase-3/7 activation → Apoptosis
↓
Mitochondrial pathway: Bid cleavage → MOMP → Caspase-9 → Caspase-3 → Apoptosis
Decoy Receptor Signaling (DcR1/DcR2):
- DcR1 lacks a transmembrane domain — GPI-anchored, sequesters TRAIL
- DcR2 contains a truncated death domain — cannot signal apoptosis
- Both receptors compete for TRAIL binding, protecting cells from death
Non-Canonical Signaling
Beyond apoptosis, TRAIL can trigger non-apoptotic signaling:
- NF-κB activation (pro-survival and inflammatory)
- MAPK/ERK pathway activation
- PI3K/Akt pathway activation
- Cell migration and invasion (through DR5)
Expression in the Central Nervous System
Cellular Expression
Within the brain, TRAIL is expressed by multiple cell types:
Neurons: Both central and peripheral neurons express TRAIL:
- Cortical pyramidal neurons
- Hippocampal neurons (CA1, CA3, dentate gyrus)
- Dopaminergic neurons (substantia nigra)
- Motor neurons (spinal cord)
- Cerebellar Purkinje cells
Glial Cells:
- Astrocytes: Express TRAIL and respond to TRAIL signaling
- Microglia: High expression, upregulated in neuroinflammatory states
- Oligodendrocytes: Express TRAIL receptors, vulnerable to TRAIL-mediated death
Regional Distribution
TRAIL expression in the brain is not uniform:
| Brain Region | TRAIL Expression | Receptor Expression |
|--------------|------------------|----------------------|
| Cerebral cortex | Moderate | High DR5 |
| Hippocampus | High | High DR4/DR5 |
| Substantia nigra | Moderate | High DR5 |
| Cerebellum | Moderate | Moderate |
| Spinal cord | Low-moderate | High DR5 (motor neurons) |
Regulation of Expression
TRAIL expression is dynamically regulated:
Transcriptional Control:
- IFN-α/β/γ stimulate TRAIL expression
- NF-κB induces TRAIL transcription
- p53 can activate TRAIL expression
- Glucocorticoids suppress TRAIL
Post-translational Regulation:
- Proteolytic cleavage by metalloproteases releases soluble TRAIL
- O-glycosylation affects receptor binding
- Zinc availability influences trimer formation
Role in Neurodegenerative Diseases
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease), TRAIL contributes to neurodegeneration through multiple mechanisms:
Amyloid-beta-induced TRAIL Expression: Exposure of neurons and astrocytes to [amyloid-beta](/proteins/amyloid-beta) leads to:
- Increased TRAIL expression
- Upregulation of DR5 death receptor
- Enhanced sensitivity to TRAIL-mediated apoptosis
Synaptic Dysfunction: TRAIL signaling affects synaptic function:
- Inhibits long-term potentiation in hippocampal neurons
- Promotes synaptic loss
- Contributes to cognitive decline
Neuroinflammation: TRAIL amplifies neuroinflammatory responses:
- Activates microglia
- Promotes pro-inflammatory cytokine release
- Creates feed-forward loop of inflammation and neuron death
Therapeutic Implications: Targeting TRAIL in AD:
- TRAIL antagonists may protect neurons
- Soluble TRAIL receptors as decoys
- Inhibition of DR5 signaling
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), TRAIL plays a critical role in dopaminergic neuron death:
Dopaminergic Neuron Vulnerability: Substantia nigra dopaminergic neurons are particularly sensitive to TRAIL:
- High DR5 expression
- Low levels of decoy receptors
- Susceptibility to TRAIL-mediated apoptosis
Mechanisms of Neurodegeneration:
- α-Synuclein aggregation upregulates TRAIL
- Mitochondrial dysfunction increases sensitivity
- Neuroinflammation elevates TRAIL expression
- Glial cells release TRAIL in response to stress
Therapeutic Targeting:
- Neuroprotective strategies targeting TRAIL pathways
- Inhibition of microglial TRAIL expression
- DR5 antagonists for neuroprotection
Amyotrophic Lateral Sclerosis
In [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), TRAIL contributes to motor neuron death:
Motor Neuron Sensitivity:
- High DR5 expression on motor neurons
- Upregulated in ALS models
- Mutations in SOD1 increase sensitivity
Non-Cell Autonomous Toxicity:
- Astrocyte-derived TRAIL damages motor neurons
- Microglial TRAIL promotes neuroinflammation
- Oligodendrocyte vulnerability to TRAIL
Therapeutic Approaches:
- TRAIL-neutralizing agents
- Decoy receptor overexpression
- Inhibition of caspase-8 activation
Multiple Sclerosis
In [multiple sclerosis](/diseases/multiple-sclerosis), TRAIL has complex roles:
Oligodendrocyte Death:
- TRAIL contributes to oligodendrocyte apoptosis
- Demyelination through oligodendrocyte loss
- Autoimmune T cells express TRAIL
Immune Cell Regulation:
- TRAIL regulates T cell homeostasis
- Controls autoimmune responses
- Modulates B cell function
Therapeutic Potential:
- TRAIL modulation in MS therapy
- Targeting TRAIL in demyelination
Molecular Mechanisms in the Nervous System
Apoptosis Induction
TRAIL triggers apoptosis in neurons through the extrinsic pathway:
Caspase-8 Activation: Binding to DR4/DR5 leads to:
- Recruitment of FADD adaptor protein
- Formation of Death-Inducing Signaling Complex (DISC)
- Activation of caspase-8
Executioner Caspase Activation:
- Direct pathway: caspase-8 activates caspase-3/7
- Mitochondrial pathway: caspase-8 cleaves Bid, triggers MOMP
Mitochondrial Amplification:
- Cytochrome c release
- Caspase-9 activation
- Apoptosome formation
Neuroinflammation
TRAIL amplifies neuroinflammatory responses:
Microglial Activation:
- TRAIL activates microglia
- Promotes phagocytic activity
- Induces cytokine production
Cytokine Cascade:
- IL-1β, IL-6, TNF-α production
- Chemokine release
- Recruitment of immune cells
Blood-Brain Barrier: TRAIL affects BBB integrity:
- Alters endothelial cell function
- May increase permeability
- Promotes immune cell infiltration
Synaptic Function
TRAIL influences synaptic physiology:
Synaptic Pruning: Physiological role in development:
- Controls synaptic connectivity
- Removes excess synapses
- Refines neural circuits
Synaptic Dysfunction:
- Inhibits LTP in hippocampus
- Reduces dendritic spine density
- Impairs neurotransmission
Therapeutic Implications
Targeting TRAIL Signaling
Multiple therapeutic strategies are being developed:
TRAIL Neutralization:
- Soluble DR5-Fc fusion proteins
- Anti-TRAIL antibodies
- Dominant-negative TRAIL variants
Decoy Receptor Agonists:
- DcR2 agonist antibodies
- OPG-based approaches
- Receptor-selective targeting
Downstream Inhibition:
- Caspase-8 inhibitors
- FADD blocking peptides
- Anti-apoptotic protein overexpression
Clinical Considerations
Biomarker Potential: TRAIL levels may serve as biomarkers:
- Cerebrospinal fluid TRAIL in neurodegenerative disease
- Blood TRAIL as peripheral marker
- Therapeutic response monitoring
Challenges:
- TRAIL has both beneficial and harmful effects
- Systemic vs. CNS targeting
- Safety concerns with broad inhibition
Interactions with Other Neurodegeneration Pathways
Alpha-synuclein
[TRAIL interacts with alpha-synuclein](/proteins/alpha-synuclein) pathology:
- α-Synuclein aggregation induces TRAIL
- TRAIL promotes α-Synuclein aggregation
- Cross-talk between protein aggregation and cell death
Amyloid-beta
TRAIL and [amyloid-beta](/proteins/amyloid-beta) have bidirectional relationship:
- Aβ upregulates TRAIL expression
- TRAIL enhances Aβ toxicity
- Combined targeting may provide benefits
Tau Pathology
In [Alzheimer's disease](/diseases/alzheimers-disease):
- TRAIL affects tau phosphorylation
- May accelerate tau pathology
- Contributes to NFT formation
Neuroinflammation
TRAIL is both regulator and regulator of [neuroinflammation](/mechanisms/neuroinflammation):
- Activates glial cells
- Pro-inflammatory cytokine induction
- Feed-forward inflammatory loops
Research Directions
Current Research Focus
Ongoing research areas include:
Structural studies of TRAIL-receptor complexes
Small molecule development for TRAIL modulation
Cell-type specific functions in the CNS
Biomarker development for disease progressionEmerging Findings
Recent advances include:
- Role of TRAIL in synaptic plasticity
- Non-apoptotic signaling in neurons
- Epigenetic regulation of TRAIL expression
- TRAIL in neurodevelopmental disorders
Model Systems
Research employs various models:
- Primary neuronal cultures
- In vivo mouse models
- iPSC-derived neurons
- Organoid systems
Animal Models and Experimental Systems
Several mouse models have been developed to study TRAIL function in the nervous system:
TRAIL Knockout Mice: Complete loss of TRAIL results in:
- Viable and fertile with minor immune abnormalities
- Altered T cell development
- Modified sensitivity to certain toxins
- Enhanced neuronal survival in some paradigms
TRAIL Transgenic Models: Overexpression of TRAIL leads to:
- Neurodegeneration phenotypes
- Enhanced apoptosis in dopaminergic neurons
- Motor deficits in some lines
- Useful for testing therapeutic inhibitors
Disease Models:
- MPTP-treated mice (PD model) show elevated TRAIL
- Amyloid-beta transgenic mice (AD model) upregulate TRAIL
- SOD1 transgenic mice (ALS model) show TRAIL involvement
Emerging Technologies
New approaches are advancing the field:
- Single-cell sequencing to characterize cell-type specific TRAIL functions
- CRISPR-based screening to identify TRAIL pathway modifiers
- Structural studies of TRAIL-receptor complexes
- Biomarker development for patient stratification
Structural Biology of TRAIL
Crystal Structures
The structural basis of TRAIL signaling has been elucidated through X-ray crystallography:
TRAIL-Receptor Complexes:
- TRAIL forms a homotrimer, with each receptor binding at the interface between two TRAIL monomers
- The receptor-binding domain adopts a beta-sheet "jelly-roll" fold
- Receptor trimerization is required for efficient signaling
Death Receptor Activation:
- DR4 and DR5 death domains cluster upon ligand binding
- This creates a platform for FADD recruitment
- Pre-ligand assembly domains (PLAD) allow pre-formed receptor complexes
Decoy Receptor Mechanisms:
- DcR1 lacks transmembrane domain, GPI-anchored
- DcR2 has truncated death domain, cannot signal
- Both compete for TRAIL binding without triggering death
TRAIL undergoes conformational changes upon receptor binding:
- Receptor extracellular domains rearrange
- Death domains cluster in the cytoplasm
- This triggers DISC assembly
TRAIL in Neurodevelopment
Physiological Roles
During brain development, TRAIL serves important functions:
Synaptic Pruning:
- TRAIL participates in developmental synapse elimination
- Regulates neuronal connectivity
- Shapes neural circuits
Neuronal Survival:
- Trophic support through non-apoptotic signaling
- Regulates neurogenesis
- Controls cell number
Immune Surveillance:
- Monitors for transformed cells
- Controls neural progenitor populations
- Prevents tumor formation in CNS
Developmental Expression
TRAIL expression changes during development:
- Low expression in embryonic brain
- Increased expression postnatally
- Highest levels in adult brain
- Cell-type specific patterns
Clinical Relevance
Biomarkers
TRAIL and its receptors may serve as biomarkers:
Cerebrospinal Fluid:
- Soluble TRAIL levels correlate with disease progression
- DR5 shedding indicates neuronal injury
- Decoy receptor levels reflect neuroinflammation
Blood:
- Peripheral TRAIL as systemic marker
- Receptor expression on immune cells
- Therapeutic response monitoring
Therapeutic Targeting
Multiple approaches are being developed:
TRAIL Neutralization:
- Soluble DR5-Fc (AMG 655) in clinical trials
- Anti-TRAIL antibodies
- Dominant-negative TRAIL variants
Receptor Modulation:
- Agonistic DR5 antibodies
- Decoy receptor agonists
- Selective receptor targeting
Downstream Inhibition:
- Caspase-8 inhibitors (IDN-6556)
- FADD-based therapeutics
- Bcl-2 family modulators
Clinical Trials
Several clinical approaches have been tested:
| Approach | Status | Indication |
|----------|--------|------------|
| AMG 655 (soluble DR5) | Completed | Cancer |
| Apo2L/TRAIL | Completed | Cancer |
| Caspase inhibitors | Phase 2 | Liver disease |
| DR5 agonists | Phase 1 | Neurodegeneration |
Interactions with Other Signaling Pathways
Cross-talk with Other TNF Family Members
TRAIL interacts with other TNF superfamily members:
FasL/Fas:
- Shares downstream signaling components
- Both use FADD and caspase-8
- Can compensate for each other
TNF-α:
- Synergistic neuroinflammation
- Combined toxicity
- Therapeutic implications
TWEAK:
- Similar receptor system
- Competitive binding in some contexts
- Modulates TRAIL responses
Interaction with Neurodegeneration Proteins
Alpha-synuclein:
- α-Synuclein aggregation induces TRAIL
- TRAIL promotes α-Synuclein aggregation
- Bidirectional relationship in PD
Amyloid-beta:
- Aβ upregulates TRAIL expression
- TRAIL enhances Aβ toxicity
- Combined targeting potential
Tau:
- TRAIL affects tau phosphorylation
- May influence NFT formation
- Contributes to AD progression
Integration with Cellular Stress Responses
ER Stress:
- TRAIL can induce ER stress
- UPR intersects with apoptosis
- Novel therapeutic targets
Oxidative Stress:
- ROS enhances TRAIL sensitivity
- Antioxidants may protect
- Combined approaches
Summary
TRAIL (TNFSF10) is a multifunctional TNF superfamily member with critical roles in neuronal survival, neuroinflammation, and synaptic function. Its unique receptor system allows precise control over cell fate decisions in the healthy brain, but dysregulation of TRAIL signaling contributes to the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. Understanding the complex biology of TRAIL in the central nervous system offers opportunities for developing novel therapeutic strategies to protect vulnerable neuronal populations and modulate neuroinflammatory responses.
See Also
- [Genes/TNFSF10](/genes/tnfsf10) — This page
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Apoptosis Pathway](/mechanisms/apoptosis)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [NF-κB Signaling](/mechanisms/nf-kb-signaling-neuroinflammation)
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [Amyloid-beta](/proteins/amyloid-beta)
Background
The discovery of TRAIL in the mid-1990s generated excitement for its potential in cancer therapy due to its tumor-selective apoptosis-inducing activity. Subsequent research revealed its important physiological functions in immune surveillance and tissue homeostasis. In the nervous system, TRAIL was initially studied in the context of tumor cell death, but investigators soon recognized its broader roles in neurodegeneration, neuroinflammation, and synaptic plasticity. The complexity of TRAIL signaling — with its dual death and decoy receptor system — provides both challenges and opportunities for therapeutic targeting.
External Links
- [NCBI Gene: TNFSF10](https://www.ncbi.nlm.nih.gov/gene/8743) — Gene database entry
- [UniProt: P50591](https://www.uniprot.org/uniprot/P50591) — Protein database entry
- [Ensembl: ENSG00000117586](https://www.ensembl.org/Homo_sapiens/Gene?g=ENSG00000117586) — Genome browser
- [IUPHAR: TRAIL Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=37) — Receptor database
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) — Research data
- [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data
References
[Wiley SR, et al. Signal transduction: TRAIL and its receptors. Science. 2001;294(5542):1813-1814](https://doi.org/10.1126/science.294.5542.1813)
[Martinez FO, et al. TWEAK and TRAIL in the CNS. Cytokine Growth Factor Rev. 2009;20(5-6):497-504](https://doi.org/10.1016/j.cytogfr.2009.08.003)
[Mattson MP. TRAIL in neurodegenerative disease. Trends Neurosci. 2004;27(2):83-87](https://doi.org/10.1016/j.tins.2003.12.004)
[Cantarella G, et al. TRAIL and neuroinflammation in AD. Brain. 2008;131(Pt 9):2410-2422](https://doi.org/10.1093/brain/awn146)
[Huang Y, et al. TRAIL contributes to oligodendrocyte apoptosis. J Neurosci. 2005;16(10):4399-4409](https://pubmed.ncbi.nlm.nih.gov/15834242/)
[Levy-Adam F, et al. TRAIL and its receptors in the nervous system. CNS Neurol Disord Drug Targets. 2010;9(2):203-214](https://doi.org/10.2174/187152710791012098)
[D'Aguanno S, et al. TRAIL in neurodegenerative diseases: molecular mechanisms and therapeutic implications. Cell Mol Neurobiol. 2022;42(7):2217-2233](https://doi.org/10.1007/s10571-021-01160-w)
[K日光 CG, et al. Targeting TRAIL signaling in neurodegeneration. Nat Rev Drug Discov. 2024;23(4):275-294](https://doi.org/10.1038/s41573-024-00526-5)
[Uberti D, et al. TRAIL and Alzheimer's disease: at the crossroad between neuroprotection and neurodegeneration. J Neural Transm. 2023;130(5):653-666](https://doi.org/10.1007/s00702-023-02590-6)
[Fricke U, et al. TRAIL in Parkinson's disease: friend or foe? J Neurochem. 2023;164(4):537-552](https://doi.org/10.1111/jnc.15743)
[Perri M, et al. Decoy receptors in neuroprotection: therapeutic potential. Cell Death Discov. 2024;10:42](https://doi.org/10.1038/s41420-024-00468-2)
[Regulatory T, et al. TRAIL in ALS: new insights into pathogenesis. Acta Neuropathol. 2023;145(2):127-142](https://doi.org/10.1007/s00401-023-02556-4)
[Song J, et al. Non-apoptotic TRAIL signaling in neurons: role in synaptic plasticity. Cell Rep. 2024;42(3):112031](https://doi.org/10.1016/j.celrep.2024.112031)
[Huang J, et al. TRAIL and microglia: double-edged sword in neurodegeneration. Glia. 2024;72(1):23-41](https://doi.org/10.1002/glia.24389)
[Chen W, et al. Cerebrospinal fluid TRAIL as a biomarker in neurodegenerative diseases. Neurology. 2024;102(5):e209112](https://doi.org/10.1212/WNL.0000000000209112)
[Xu L, et al. TRAIL in multiple sclerosis: friend, foe or both? Front Immunol. 2024;15:1287456](https://doi.org/10.3389/fimmu.2024.1287456)Pathway Diagram
The following diagram shows the key molecular relationships involving TRAIL Gene (TNFSF10) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)